Abstract:Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenylacetic acid. Phenylacetic acid can be converted to phenylacetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome. Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV. Methods The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis. Results Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome. Conclusions The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.

Amino acid metabolism dysregulation associated with inflammation and insulin resistance in HIV-infected individuals with metabolic disorders

Severe Dyslipidemia and Immune Activation in HIV Patients with Dysglycemia

Altered plasma metabolites and inflammatory networks in HIV-1 infected patients with different immunological responses after long-term antiretroviral therapy

Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease

The altered metabolites contributed by dysbiosis of gut microbiota are associated with microbial translocation and immune activation during HIV infection

Comprehensive Metabolomics Profiling Reveals Common Metabolic Alterations Underlying the Four Major Non-Communicable Diseases in Treated HIV Infection

Systems Analysis of Gut Microbiome Influence on Metabolic Disease in HIV-Positive and High-Risk Populations

Metabolic profiling of HIV infected individuals on an AZT-based antiretroviral treatment regimen reveals persistent oxidative stress

People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites: a case–control study

Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: an Observational Study in A Chinese Population

Dysbiosis of gut microbiota and metabolites during AIDS: implications for CD4+ T cell reduction and immune activation

The Association between IL-1β and IL-18 Levels, Gut Barrier Disruption, and Monocyte Activation during Chronic Simian Immunodeficiency Virus Infection and Long-Term Suppressive Antiretroviral Therapy

Brain function abnormalities and neuroinflammation in people living with HIV-associated anxiety disorders

Evaluation of lipid metabolism imbalance in HIV-infected patients with metabolic disorders using high-performance liquid chromatography-tandem mass spectrometry

Altered Metabolism in Right Basal Ganglia Associated with Asymptomatic Neurocognitive Impairment in HIV-infected Individuals

Cytokine and chemokine receptor profiles in adipose tissue vasculature unravel endothelial cell responses in HIV

Characterization of intestinal fungal community diversity in people living with HIV/AIDS (PLWHA)

Analysis of the gut microbiota and fecal metabolites in people living with HIV

Exploring salivary metabolome alterations in people with HIV: towards early diagnostic markers

Inflammatory Markers and Plasma Lipids in HIV Patients: A Correlation Analysis Study

Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy